[en] Regulatory T cells (Tregs) are essential to prevent autoimmunity, but excessive Treg function contributes to cancer progression by inhibiting antitumor immune responses. Tregs exert contact-dependent inhibition of immune cells through the production of active transforming growth factor–b1 (TGF-b1). On the Treg cell surface, TGF-b1 is in an inactive form bound to membrane protein GARP and then activated by an unknown mechanism. We demonstrate that GARP is involved in this activation mechanism. Two anti-GARP monoclonal antibodies were generated that
block the production of active TGF-b1 by human Tregs. These antibodies recognize a conformational epitope that requires amino acids GARP137–139 within GARP/TGF-b1 complexes. A variety of antibodies recognizing other GARP epitopes did not block active TGF-b1 production by Tregs. In a model of xenogeneic graft-versus-host disease in NSG mice, the blocking antibodies inhibited the immunosuppressive activity of human Tregs. These antibodies may serve as therapeutic tools to boost immune responses to infection or cancer via a mechanism of action distinct from that of currently available immunomodulatory antibodies. Used alone or in combination with tumor vaccines or antibodies targeting the CTLA4 or PD1/PD-L1 pathways, blocking anti-GARP antibodies may improve the efficiency of cancer immunotherapy.
Y. Zheng, A. Y. Rudensky, Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8, 457-462 (2007).
S. Sakaguchi, M. Miyara, C. M. Costantino, D. A. Hafler, FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
Y. Zheng, S. Josefowicz, A. Chaudhry, X. P. Peng, K. Forbush, A. Y. Rudensky, Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463, 808-812 (2010).
J. Stockis, W. Fink, V. François, T. Connerotte, C. de Smet, L. Knoops, P. van der Bruggen, T. Boon, P. G. Coulie, S. Lucas, Comparison of stable human Treg and Th clones by transcriptional profiling. Eur. J. Immunol. 39, 869-882 (2009).
S. Floess, J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H.-D. Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, A. Hamann, J. Huehn, Epigenetic control of the foxp3 locus in regulatory T cells. PLOS Biol. 5, e38 (2007).
G. Wieczorek, A. Asemissen, F. Model, I. Turbachova, S. Floess, V. Liebenberg, U. Baron, D. Stauch, K. Kotsch, J. Pratschke, A. Hamann, C. Loddenkemper, H. Stein, H. D. Volk, U. Hoffmüller, A. Grützkau, A. Mustea, J. Huehn, C. Scheibenbogen, S. Olek, Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 69, 599-608 (2009).
I. J. de Vries, C. Castelli, C. Huygens, J. F. Jacobs, J. Stockis, B. Schuler-Thurner, G. J. Adema, C. J. Punt, L. Rivoltini, G. Schuler, P. G. Coulie, S. Lucas, Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin. Cancer Res. 17, 841-848 (2011).
U.Baron,S.Floess,G.Wieczorek,K.Baumann,A.Grützkau,J.Dong,A.Thiel,T.J.Boeld, P. Hoffmann, M. Edinger, I. Türbachova, A. Hamann, S. Olek, J. Huehn, DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur. J. Immunol. 37, 2378-2389 (2007).
M. Miyara, Y. Ito, S. Sakaguchi, TREG-cell therapies for autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 10, 543-551 (2014).
C. Ménétrier-Caux, T. Curiel, J. Faget, M. Manuel, C. Caux, W. Zou, Targeting regulatory T cells. Target. Oncol. 7, 15-28 (2012).
J. F. M. Jacobs, S. Nierkens, C. G. Figdor, I. J. M. de Vries, G. J. Adema, Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol. 13, e32-e42 (2012).
S. Z. Josefowicz, L.-F. Lu, A. Y. Rudensky, Regulatory T cells: Mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. Robertson, R. A. Flavell, Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
M. M. Shull, I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, N. Annunziata, T. Doetschman, Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
J. Massague, TGFβ in cancer. Cell 134, 215-230 (2008).
J. C. Morris, A. R. Tan, T. E. Olencki, G. I. Shapiro, B. J. Dezube, M. Reiss, F. J. Hsu, J. A. Berzofsky, D. P. Lawrence, Phase I study of GC1008 (fresolimumab): A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLOS One 9, e90353 (2014).
S. Lonning, J. Mannick, J. M. McPherson, Antibody targeting of TGF-β in cancer patients. Curr. Pharm. Biotechnol. 12, 2176-2189 (2011).
M. A. Travis, D. Sheppard, TGF-β activation and function in immunity. Annu. Rev. Immunol. 32, 51-82 (2014).
J. Stockis, D. Colau, P. G. Coulie, S. Lucas, Membrane protein GARP is a receptor for latent TGF-β on the surface of activated human Treg. Eur. J. Immunol. 39, 3315-3322 (2009).
J. H. Kehrl, L. M. Wakefield, A. B. Roberts, S. Jakowlew, M. Alvarez-Mon, R. Derynck, M. B. Sporn, A. S. Fauci, Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163, 1037-1050 (1986).
K. Nakamura, A. Kitani, W. Strober, Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644 (2001).
K. Nakamura, A. Kitani, I. Fuss, A. Pedersen, N. Harada, H. Nawata, W. Strober, TGF-β1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842 (2004).
D. Q. Tran, J. Andersson, R. Wang, H. Ramsey, D. Unutmaz, E. M. Shevach, GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 106, 13445-13450 (2009).
R. Wang, Q. Wan, L. Kozhaya, H. Fujii, D. Unutmaz, Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLOS One 3, e2705 (2008).
M. Probst-Kepper, R. Geffers, A. Kröger, N. Viegas, C. Erck, H.-J. Hecht, H. Lünsdorf, R. Roubin, D. Moharregh-Khiabani, K. Wagner, F. Ocklenburg, A. Jeron, H. Garritsen, T. P. Arstila, E. Kekäläinen, R. Balling, H. Hauser, J. Buer, S. Weiss, GARP: A key receptor controlling FOXP3 in human regulatory T cells. J. Cell. Mol. Med. 13, 3343-3357 (2009).
C. Basilico, A. Hultberg, C. Blanchetot, N. de Jonge, E. Festjens, V. Hanssens, S.-I. Osepa, G. De Boeck, A. Mira, M. Cazzanti, V. Morello, T. Dreier, M. Saunders, H. de Haard,P. Michieli, Four individually druggable MET hotspots mediate HGF-driven tumor progression. J. Clin. Invest. 124, 3172-3186 (2014).
L. D. Shultz, M. A. Brehm, J. V. Garcia-Martinez, D. L. Greiner, Humanized mice for immune system investigation: Progress, promise and challenges. Nat. Rev. Immunol. 12, 786-798 (2012).
M. Hannon, C. Lechanteur, S. Lucas, J. Somja, L. Seidel, L. Belle, F. Bruck, E. Baudoux, O. Giet, A.-M. Chantillon, P. Delvenne, P. Drion, Y. Beguin, S. Humblet-Baron, F. Baron, Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft'-versushost disease. Transfusion 54, 353-363 (2014).
M. B. Overdijk, S. Verploegen, A. Ortiz Buijsse, T. Vink, J. H. W. Leusen, W. K. Bleeker, P. W. H. I. Parren, Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189, 3430-3438 (2012).
M. H. Tao, S. L. Morrison, Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595-2601 (1989).
M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z. Amoura, G. Gorochov, S. Sakaguchi, Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899-911 (2009).
R. Wang, J. Zhu, X. Dong, M. Shi, C. Lu, T. A. Springer, GARP regulates the bioavailability and activation of TGFβ. Mol. Biol. Cell 23, 1129-1139 (2012).
E. Gauthy, J. Cuende, J. Stockis, C. Huygens, B. Lethé, J.-F. Collet, G. Bommer, P. G. Coulie, S. Lucas, GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells. PLOS One 8, e76186 (2013).
J. P. Edwards, H. Fujii, A. X. Zhou, J. Creemers, D. Unutmaz, E. M. Shevach, Regulation of the expression of GARP/latent TGF-β1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J. Immunol. 190, 5506-5515 (2013).
J. P. Edwards, A. M. Thornton, E. M. Shevach, Release of active TGF-β1 from the latent TGF-β1/GARP complex on T regulatory cells is mediated by integrin β8. J. Immunol. 193, 2843-2849 (2014).
R. Roubin, S. Pizette, V. Ollendorff, J. Planche, D. Birnbaum, O. Delapeyriere, Structure and developmental expression of mouse Garp, a gene encoding a new leucine-rich repeat-containing protein. Int. J. Dev. Biol. 40, 545-555 (1996).
M. N. O'Connor,I.I.Salles,A.Cvejic,N.A.Watkins,A.Walker,S.F.Garner,C.I.Jones,I.C.Macaulay, M. Steward, J.-J. Zwaginga, S. L. Bray, F. Dudbridge, B. de Bono, A. H. Goodall, H. Deckmyn, D. L. Stemple, W. H. Ouwehand, Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood 113, 4754-4762 (2009).
I. C. Macaulay, M. R. Tijssen, D. C. Thijssen-Timmer,A.Gusnanto, M.Steward, P.Burns, C.F.Langford, P. D. Ellis, F. Dudbridge, J.-J. Zwaginga, N. A. Watkins, C. E. van der Schoot, W. H. Ouwehand, Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood 109, 3260-3269 (2007).
A. Kehrmann, H. Truong, A. Repenning, R. Boger, L. Klein-Hitpass, U. Pascheberg, A. Beckmann, B. Opalka, K. Kleine-Lowinski, Complementation of non-tumorigenicity of HPV18-positive cervical carcinoma cells involves differential mRNA expression of cellular genes including potential tumor suppressor genes on chromosome 11q13. Cancer Genet. 206,279-292 (2013).
C. A. Piccirillo, J. J. Letterio, A. M. Thornton, R. S. McHugh, M. Mamura, H. Mizuhara, E.M. Shevach, CD4+CD25+ regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J. Exp. Med. 196, 237-246 (2002).
M. O. Li, Y. Y. Wan, R. A. Flavell, T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26, 579-591 (2007).
L. Fahlén, S. Read, L. Gorelik, S. D. Hurst, R. L. Coffman, R. A. Flavell, F. Powrie, T cells that cannot respond to TGF-β escape control by CD4+CD25+ regulatory T cells. J. Exp. Med. 201, 737-746 (2005).
J. C. Marie, D. Liggitt, A. Y. Rudensky, Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 25, 441-454 (2006).
M. O. Li, S. Sanjabi, R. A. Flavell, Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25, 455-471 (2006).
Y. Liu, P. Zhang, J. Li, A. B. Kulkarni, S. Perruche, W. Chen, A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat. Immunol. 9, 632-640 (2008).
D. B. Page, M. A. Postow, M. K. Callahan, J. P. Allison, J. D. Wolchok, Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185-202 (2014).
T. R. Simpson, F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, J. V. Ravetch, J. P. Allison, S. A. Quezada, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
M. J. Selby, J. J. Engelhardt, M. Quigley, K. A. Henning, T. Chen, M. Srinivasan, A. J. Korman, Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1,32-42 (2013).
J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan,R. -A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, J.-F. Baurain, A. Testori, J.-J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. H. Miller Jr., P. Gascon, M.Lotem,K.Harmankaya,R.Ibrahim,S.Francis,T.-T.Chen,R.Humphrey,A.Hoos,J.D.Wolchok, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. M. van den Eertwegh, J. Lutzky, P.Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
A. Van Pel, E. De Plaen, T. Boon, Selection of highly transfectable variant from mouse mastocytoma P815. Somat. Cell Mol. Genet. 11, 467-475 (1985).
M. M. Lemaire, A. Vanhaudenarde, Y. Nizet, L. Dumoutier, J.-C. Renauld, Induction of autoantibodies against mouse soluble proteins after immunization with living cells presenting the autoantigen at the cell surface in fusion with a human type 2 transmembrane protein. J. Immunol. 367, 56-62 (2011).
L. P. Daley, L. F. Gagliardo, M. S. Duffy, M. C. Smith, J. A. Appleton, Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids. Clin. Diagn. Lab. Immunol. 12, 380-386 (2005).
P. Chomczynski, N. Sacchi, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159 (1987).
C. Uyttenhove, R. G. Marillier, F. Tacchini-Cottier, M. Charmoy, R. R. Caspi, J. M. Damsker, S. Goriely, D. Su, J. Van Damme, S. Struyf, G. Opdenakker, J. Van Snick, Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: Perspectives illustrated for GCP-2 in L. major infection. J. Leukoc. Biol. 89, 1001-1007 (2011).
P. G. Coulie, J. Van Snick, Enhancement of IgG anti-carrier responses by IgG2 anti-hapten antibodies in mice. Eur. J. Immunol. 15, 793-798 (1985).
